New findings from the National Pregnancy Registry for Atypical Antipsychotics provide reassuring data regarding the safety of prenatal exposure to lurasidone and quetiapine in a sample of well-characterized participants.
Maternal depression during the third trimester, not prenatal SSRI exposure, was associated with higher levels of internalizing and anxiety behaviors in children from 3 to 12 years of age.
A recently published article in the American Journal of Public Health has attributed a substantial financial cost to untreated perinatal mood and anxiety disorders among mothers. The study, conducted by researchers with the think [...]
As women transition into the menopause, they experience a constellation of symptoms including vasomotor symptoms (hot flashes and night sweats), sleep disruption, problems with sexual functioning, and cognitive impairment. Women may also be more [...]
In 2008, the National Institutes of Health funded the Menopause Strategies: Finding Lasting Answers for Symptoms and Health or MSFlash clinical trials network. The primary goal of MSFlash has been to find and test [...]
The newer “atypical” or second-generation antipsychotic agents are now used to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders. The National Pregnancy Registry for Atypical Antipsychotics [...]
